Imovax Polio

Poliovirus (Inactivated) Type 3 (Saukett Strain) and Poliovirus (Inactivated) Type 2 (Mef-1 Strain), the active ingredient in Imovax Polio, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It prevents poliomyelitis by inducing immunity against poliovirus types 2 and 3.

GNH USA supplies Imovax Polio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imovax Polio is an inactivated poliovirus vaccine used in the prevention of poliomyelitis.

- Poliomyelitis: Provides active immunity that protects against infection with poliovirus types 2 and 3. - Travel to endemic regions: Reduces the risk of acquiring poliovirus during international travel. - Outbreak response: Supports mass‑immunisation campaigns aimed at controlling poliovirus outbreaks.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site of administration. - Redness or swelling: localized erythema or edema that resolves within a few days. - Low‑grade fever: transient elevation of body temperature. - Headache: mild headache occurring within 24 hours. - Fatigue: temporary tiredness after vaccination. - Muscle aches: mild myalgia at the injection site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder presenting with muscle weakness. - Seizures: uncommon convulsive episodes. - Severe hypotension: marked drop in blood pressure post‑injection. - Extensive rash or urticaria: widespread skin eruption. - Encephalitis: extremely rare inflammation of the brain.

Before administering Imovax Polio, consider the following precautions: - Allergy screening: avoid use in individuals with severe hypersensitivity to any vaccine component. - Pregnancy: consult a healthcare provider; limited safety data are available. - Immunocompromised patients: vaccine may elicit a reduced immune response. - Concomitant vaccines: follow recommended immunisation schedules to avoid interference. - Post‑vaccination observation: monitor for immediate adverse reactions for at least 15 minutes. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Imovax Polio may interact with other agents as follows:

Major Interactions (Avoid): - Live viral vaccines: avoid simultaneous administration to prevent immune interference. - Immunoglobulin therapy: may diminish vaccine‑induced antibody response. - Blood products: can reduce immunogenicity if given shortly before or after vaccination.

Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen, ibuprofen): may mask fever, a sign of reaction. - Immunosuppressive drugs: may lower the effectiveness of the vaccine and require serologic monitoring.